Aktis Oncology (AKTS)

Executive Summary

Aktis Oncology is a publicly traded biotechnology company pioneering a novel class of targeted alpha radiopharmaceuticals for solid tumors. The company's proprietary miniprotein radioconjugate platform is designed to deliver potent alpha-emitting isotopes directly to cancer cells, potentially expanding the therapeutic reach of radiopharmaceuticals to tumor types and patient populations not previously addressable. With a valuation of approximately $1.1 billion and a focus on precision oncology, Aktis is positioned at the forefront of the next wave of radiopharmaceutical innovation. The platform's small size and favorable pharmacokinetics may enable deeper tumor penetration and faster clearance, reducing off-target toxicity. As the company progresses toward clinical development, its technology has the potential to address high unmet needs across multiple prevalent solid tumors.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1 clinical trial for lead miniprotein radioconjugate candidate in solid tumors70% success
• TBDPresentation of preclinical in vivo efficacy and safety data for pipeline programs at a major medical conference80% success
• TBDAnnouncement of strategic partnership or licensing deal for platform technology with a large pharmaceutical company50% success